Aquestive Therapeutics, Inc. (AQST) is a Drug manufacturers specialty generic company in the Healthcare sector, listed on Nasdaq.
This page provides the complete earnings calendar, dividend schedule, and financial data for Aquestive Therapeutics, Inc. in 2026. The next earnings report is expected on November 9, 2026.
Aquestive Therapeutics missed consensus on EPS but revenue exceeded estimates in the latest earnings report, with EPS of $-0.18 missing the $-0.105 estimate and revenue of $13.82 million exceeding estimates by 21.0%. Both EPS and revenue were ahead of expectations in the previous report.
Dividend calendar
No dividend history available.
EPS (Earnings Per Share)
Revenue
Company profile
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
